Аннотация
Начавшаяся в конце 2019 г. вспышка COVID-19 является беспрецедентным по масштабам и последствиям событием в новейшей истории человечества. На 27 мая 2020 г. во всем мире официально зарегистрировано 5 618 829 случаев заражения человека SARS-CoV-2 и 351 146 случаев гибели в результате развития инфекции по данным коронавирусного ресурсного центра университета Джона Хопкинза. В базе данных публикаций PubMed 16490 работ содержат в своем названии «COVID-19». Благодаря современным информационным технологиям данные о распространении и клиническом течении COVID-19 становятся общедоступными практически в режиме реального времени. В то же время детали происхождения возбудителя, тропности вируса, способы распространения инфекции, методы лабораторной диагностики и возможные подходы к специфической терапии остаются предметом активного дальнейшего изучения. В данном обзоре представлен анализ актуальной литературы, описывающей поставленные вопросы.
Литература
1. World Health Organization (WHO). Novel Coronavirus (2019-nCoV) Situation Report - 1 21 January 2020 // WHO Bull. 2020. №. JANUARY. P. 1–8.
2. Chan J.F.W. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster // Lancet. – 2020. – V. 395. – №. 10223. –P. 514–523. doi: 10.1016/S0140-6736(20)30154-9.
3. Corman V.M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR // Eurosurveillance. – 2020. – V. 25. – №. 3. – P. 1–8. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
4. World Health Organization (WHO). Novel Coronavirus (2019-nCoV ) Situation Report - 22 11 February 2020 // WHO Bull. 2020. №. February. P. 1–7.
5. Gorbalenya A.E. et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nat. Microbiol. – 2020. – V. 5. – №. 4. – P. 536–544. doi: 10.1038/s41564-020-0695-z.
6. World Health Organization (WHO). Coronavirus (COVID-19) Situation Report - 51 11 March 2020 // WHO Bull. 2020. P. 1–9.
7. Bukhari K. et al. Description and initial characterization of metatranscriptomic nidovirus-like genomes from the proposed new family Abyssoviridae, and from a sister group to the Coronavirinae, the proposed genus Alphaletovirus // Virology. – 2018. V. 524. – P. 160–171. doi: 10.1016/j.virol.2018.08.010.
8. Su S. et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses // Trends Microbiol. – 2016. – V. 24. – №. 6. – P. 490–502. doi: 10.1016/j.tim.2016.03.003.
9. Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses // Nat. Rev. Microbiol. – 2019. –V. 17. – №. 3. – P. 181–192. doi: 10.1038/s41579-018-0118-9.
10. Anderson R.M. et al. Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic // Philos. Trans. R. Soc. London. Ser. B Biol. Sci. / ed. May R.M. et al. – 2004. – V. 359. – №. 1447. – P. 1091–1105. doi: 10.1098/rstb.2004.1490.
11. The WHO MERS-CoV Research Group -. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans // PLoS Curr. – 2013. – V. 5. – P. 1–18. doi: 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
12. Zumla A., Hui D.S., Perlman S. Middle East respiratory syndrome // Lancet. –2015. V. 386. – №. 9997. – P. 995–1007. doi: 10.1016/S0140-6736(15)60454-8
13. Cho S.Y. et al. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study // Lancet. – 2016. – V. 388. – №. 10048. – P. 994–1001. doi: 10.1016/S0140-6736(16)30623-7.
14. Oh M.D. et al. Middle east respiratory syndrome: What we learned from the 2015 outbreak in the republic of Korea // Korean J. Intern. Med. – 2018. – V. 33. – №. 2. – P. 233–246. doi: 10.3904/kjim.2018.031.
15. Andersen K.G. et al. The Proximal Origin of SARS-CoV-2 // Virological. – 2020. – №. 2. – P. 1–7. doi: 10.2106/JBJS.F.00094.
16. Zhou P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin // Nature. – 2020. – V. 579. – №. 7798. – P. 270–273. doi: 10.1038/s41586-020-2012-7.
17. Normile D. Novel human virus? Pneumonia cases linked to seafood market in China stir concern. .https://www.sciencemag.org/news/2020/01/novel-human-virus-pneumonia-cases-linked-seafood-market-china-stir-concern
18. Hoffmann M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor // Cell. – 2020. – V. 181. – №. 2. – P. 271-280.e8. doi: 10.1016/j.cell.2020.02.052.
19. South A.M., Diz D.I., Chappell M.C. COVID-19, ACE2, and the cardiovascular consequences // Am. J. Physiol. Heart Circ. Physiol. – 2020. – V. 318. – №. 5. – P. H1084–H1090. doi: 10.1152/ajpheart.00217.2020.
20. Kuster G.M. et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? // Eur. Heart J. – 2020. – P. 1–3. doi: 10.1093/eurheartj/ehaa235.
21. Hamming I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis // J. Pathol. – 2004. – V. 203. – №. 2. – P. 631–637. doi: 10.1002/path.1570.
22. Xu H. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa // Int. J. Oral Sci. – 2020. – V. 12. – №. 1. – P. 1–5. doi: 10.1038/s41368-020-0074-x.
23. Zhang H. et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target // Intensive Care Med. – 2020. – V. 46. – №. 4. – P. 586–590. doi: 10.1007/s00134-020-05985-9.
24. Douglas G.C. et al. The novel Angiotensin-Converting Enzyme (ACE) homolog, ACE2, is selectively expressed by adult leydig cells of the testis // Endocrinology. – 2004. – V. 145. – №. 10. – P. 4703–4711. doi: 10.1210/en.2004-0443.
25. Chen L. et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 // Cardiovasc. Res. – 2020. – P. 1097–1100. doi: 10.1093/cvr/cvaa078.
26. Uhlen M. et al. Tissue-based map of the human proteome // Science. – 2015. – V. 347. – №. 6220. – P. 1260419–1260419. doi: 10.1126/science.1260419.
27. Chen J., Subbarao K. The Immunobiology of SARS // Annu. Rev. Immunol. – 2007. – V. 25. – №. 1. – P. 443–472. doi: 10.1146/annurev.immunol.25.022106.141706.
28. Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020. – V. 395. – №. 10223. – P. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
29. Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. Elsevier Ltd. – 2020. – V. 395 – №. 10223. – P. 507–513. doi: 10.1016/S0140-6736(20)30211-7.
30. Puelles V.G. et al. Multiorgan and Renal Tropism of SARS-CoV-2 // N. Engl. J. Med. – 2020. – V. 367. – №. 22. – P. NEJMc2011400. doi: 10.1056/NEJMc2011400.
31. World Health Organization (WHO). Q&A on coronaviruses (COVID-19). WHO; 2020. URL: http://www.emro.who.int/health-topics/corona-virus/questions-and-answers.html.
32. Centers for Disease Control and Prevention (CDC). How COVID-19 Spreads. CDC; 2020. URL: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html.
33. Bourouiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 // JAMA. – 2020. – P. E1–E2. doi: 10.1001/jama.2020.4756.
34. van Doremalen N. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 // N. Engl. J. Med. – 2020. – V. 382. – №. 16. – P. 1564–1567. doi: 10.1056/NEJMc2004973.
35. Wölfel R. et al. Virological assessment of hospitalized patients with COVID-2019 // Nature. – 2020. – P. 1–14. doi: 10.1038/s41586-020-2196-x.
36. Xu Y. et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding // Nat. Med. 2020. – V. 26. – №. 4. – P. 502–505. doi: 10.1038/s41591-020-0817-4.
37. Wang W. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens // JAMA. – 2020. – P. 3–4. doi: 10.1001/jama.2020.3786.
38. Lodder W., de Roda Husman A.M. SARS-CoV-2 in wastewater: potential health risk, but also data source // lancet. Gastroenterol. Hepatol. – 2020. – V. 1253. – №. 20. – P. 30087. doi: 10.1016/S2468-1253(20)30087-X.
39. Sethuraman N., Jeremiah S.S., Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2 // JAMA. – 2020. – V. 2019. – P. 2019–2021. doi: 10.1001/jama.2020.8259.
40. Böhmer M.M. et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series // Lancet Infect. Dis. – 2020. – V. 3099. – №. 20. doi: 10.1016/S1473-3099(20)30314-5.
41. Peiris J. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study // Lancet. – 2003. – V. 361. – №. 9371. – P. 1767–1772. doi: 10.1016/S0140-6736(03)13412-5.
42. Jacofsky D., Jacofsky E.M., Jacofsky M. Understanding Antibody Testing for COVID-19 // J. Arthroplasty. – 2020. doi: 10.1016/j.arth.2020.04.055.
43. Long Q. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 // Nat. Med. – 2020. doi: 10.1038/s41591-020-0897-1.
44. COVID-19 Vaccine & Therapeutics Tracker. BioRender; 2020. URL: https://biorender.com/covid-vaccine-tracker.
45. Thanh Le T. et al. The COVID-19 vaccine development landscape // Nat. Rev. Drug Discov. Springer US. – 2020. – V. 19. – №. 5. – P. 305–306. doi: 10.1038/d41573-020-00073-5.
46. Pronker E.S. et al. Risk in Vaccine Research and Development Quantified // PLoS One / ed. Vasilakis N. – 2013. – V. 8. – №. 3. – P. e57755. doi: 10.1371/journal.pone.0057755.
47. Wang Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial // Lancet. Elsevier Ltd. – 2020. –. P. 1569–1578. doi: 10.1016/S0140-6736(20)31022-9.
48. Goldhill D.H. et al. The mechanism of resistance to favipiravir in influenza // Proc. Natl. Acad. Sci. U. S. A. – 2018. – V. 115. – №. 45. – P. 11613–11618. doi: 10.1073/pnas.1811345115.
49. Elfiky A.A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study // Life Sci. 2020. – V. 253. – P. 117592. doi: 10.1016/j.lfs.2020.117592.
50. Chary M.A. et al. COVID-19: Therapeutics and Their Toxicities // J. Med. Toxicol. Journal of Medical Toxicology. – 2020. –. P. 1–11. doi: 10.1007/s13181-020-00777-5.
51. Cao B. et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 // N. Engl. J. Med. 2020. – V. 382. – №. .19. – P. 1787–1799. doi: 10.1056/NEJMoa2001282.
52. Liu J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro // Cell Discov. 2020. – V. 6. – P. 6–9. doi: 10.1038/s41421-020-0156-0.
53. Mehra M.R. et al. Articles Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis // Lancet. Elsevier Ltd. – 2020. – V. 6736(20). – P. 1–10. doi: 10.1016/S0140-6736(20)31180-6.
54. Uno Y. Camostat mesilate therapy for COVID-19 // Intern. Emerg. Med. Springer International Publishing. – 2020. – P. 1–2. doi: 10.1007/s11739-020-02345-9.
55. Ou X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV // Nat. Commun. Springer US. – 2020. – V. 11. – P. 1620. doi: 10.1038/s41467-020-15562-9.
56. Shang J. et al. Cell entry mechanisms of SARS-CoV-2 // Proc. Natl. Acad. Sci. – 2020. – V. 2020. – P. 202003138. doi: 10.1073/pnas.2003138117.
57. Hung I.F. et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial // Lancet. Elsevier Ltd. – 2020. – V. 6736. – P. 1–10. doi: 10.1016/S0140-6736(20)31042-4.
58. Ziegler C.G.K. et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues // Cell. – 2020. – P. 1–20. doi: 10.1016/j.cell.2020.04.035.
59. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19 // J. Infect. Elsevier Ltd. – 2020. – V. 80. – P. 607–613. doi: 10.1016/j.jinf.2020.03.037.
60. Meduri G.U. et al. Inflammatory Cytokines in the BAL of Patients With ARDS // Chest. – 1995. – V. 108. – P. 1303–1314. doi: 10.1378/chest.108.5.1303.
61. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin. Immunopathol. Seminars in Immunopathology. – 2017. – V. 39. – P. 529–539. doi: 10.1007/s00281-017-0629-x.
62. Deviatkin A.A. et al. Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy // Biomedicines. – 2020. – V. 8. – P. 9. doi: 10.3390/biomedicines8010009.
63. Moore B.J.B., June C.H. Cytokine release syndrome in severe COVID-19 // Science. – 2020. – P. eabb8925. doi: 10.1126/science.abb8925
64. Feldmann M. et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed // Lancet. – 2020. – V. 395 – P. 1407–1409. doi: 10.1016/S0140-6736(20)30858-8.
65. Xu X. et al. Effective treatment of severe COVID-19 patients with tocilizumab // Proc. Natl. Acad. Sci. – 2020. – V. 117(20). – P. 10970–10975. doi: 10.1073/pnas.2005615117.
66. Michot J.-M. et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report // Ann. Oncol. European Society for Medical Oncology. – 2020. doi: 10.1016/j.annonc.2020.03.300.
67. Jose R.J., Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation // Lancet Respir. Med. – 2020. – P. 19–20. doi: 10.1016/S2213-2600(20)30216-2.
68. Levi M. et al. Coagulation abnormalities and thrombosis in patients with COVID-19 // Lancet Haematol. – 2020. – V. 20. – P. 2019–2021. doi: 10.1016/S2352-3026(20)30145-9.